Real-world evidence has a scaling problem, and it is not a shortage of data. Health systems, claims, and registries hold enormous patient populations. The bottleneck is that every source speaks its own dialect: different schemas, different codes, different conventions, so every RWE study historically became a bespoke data-engineering project before a single clinical question could be answered. Standardization is what breaks that pattern, and 2025-2026 marks the point where the pieces finally fit together.
OMOP: The Standardization That Makes Scale Possible
The OMOP Common Data Model, maintained by the OHDSI collaborative, harmonizes disparate health data into one relational structure and maps clinical terms to standard vocabularies such as SNOMED CT, RxNorm, and LOINC. The scale is now substantial: the global OHDSI network encompasses hundreds of data sources across dozens of countries, covering close to a billion patient records mapped to the same model.
The strategic payoff is reproducibility and portability. An analytic cohort defined once against OMOP can, in principle, run across many datasets and geographies without being rewritten for each one. For a life sciences team, that changes the economics of evidence generation:
- Studies become portable across data partners instead of re-engineered per source.
- Cohort definitions become reusable assets rather than one-off SQL.
- Analyses become reproducible: a growing expectation from regulators and journals alike.
The mapping work is real and should not be underestimated. But it is done once per source and amortized across every study that follows.
External Control Arms: Evidence Where a Trial Cannot Reach
Standardized real-world data unlocks one of the most valuable applications in modern drug development: the external control arm. In settings where a randomized comparator is impractical or unethical, such as rare diseases, pediatric populations, or aggressive oncology indications, a control arm can be constructed from real-world patients who meet the trial's eligibility criteria.
Doing this credibly is a methodological discipline, not a shortcut:
- Eligibility must mirror the trial's inclusion and exclusion criteria applied to the real-world source.
- Baseline balance matters. Propensity-score methods align the external cohort with the trial arm on measured confounders to make the comparison defensible.
- Transparency and pre-specification are what make regulators willing to consider the evidence.
OMOP standardization is what makes external control arms feasible at scale, because eligible patients can be identified consistently across large, harmonized populations rather than assembled by hand from incompatible sources.
Natural-Language Querying: Compressing Time-to-Question
Even with standardized data, there has been a translation tax: a clinical or medical affairs stakeholder frames a question, then waits for a programmer to render it as OMOP SQL. The 2025-2026 advance is closing that gap. New approaches pair large language models with OMOP, including Model Context Protocol servers for the common data model and agentic architectures that translate natural-language questions into validated queries.
The critical design detail is that these systems do not free-associate against raw tables. A well-built one includes a semantic layer that normalizes clinical language and abbreviations to standard OMOP concept IDs before querying, so "MI" resolves to the correct myocardial-infarction concept, not a keyword match. That grounding in standardized vocabulary is what makes natural-language querying trustworthy rather than merely convenient. This is the same principle behind natural-language querying to democratize data more broadly.
Done right, it lets an epidemiologist or medical affairs lead explore cohorts and prevalence in minutes, reserving scarce programming time for the studies that need full rigor.
Guardrails for Credible RWE
Speed cannot come at the cost of validity or privacy. A few non-negotiables:
- Human expert validation. Natural-language-generated queries are a draft for an epidemiologist or programmer to verify, especially for anything feeding a regulatory or publication-grade analysis.
- Reproducibility over convenience. Every cohort and analysis should be captured as versioned, re-runnable code, not an ephemeral chat.
- Privacy by design. Patient-level real-world data stays governed with HIPAA-aligned controls; querying does not relax them.
- Methodological transparency. For external control arms especially, pre-specify and document methods rather than tuning them to a desired result.
The Takeaway
Real-world evidence is moving from artisanal to industrial. OMOP turns incompatible data sources into a common, reproducible substrate; external control arms extend rigorous comparison into places trials cannot easily go; and natural-language querying collapses the distance between a clinical question and a validated answer, provided it is grounded in standardized vocabulary and checked by human experts. For life sciences teams, the combination means faster, more portable, more defensible evidence. The organizations that invest in the OMOP foundation now will generate evidence at a speed their competitors, still re-engineering every study from scratch, simply cannot match.